alpha-naphthoflavone has been researched along with thalidomide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bantle, JA; Finch, RA; Fort, DJ; Stover, EL | 1 |
| Cao, C; Chen, W; Hu, J; Shi, Y; Wang, L; Ye, W; Zhou, L; Zhou, W | 1 |
2 other study(ies) available for alpha-naphthoflavone and thalidomide
| Article | Year |
|---|---|
Evaluation of the developmental toxicity of thalidomide using frog embryo teratogenesis assay-xenopus (FETAX): biotransformation and detoxification.
Topics: Amitrole; Animals; Benzoflavones; Biotransformation; Cyclohexanes; Cyclohexenes; Cytochrome P-450 Enzyme System; Embryo, Nonmammalian; Embryonic Development; Enzyme Inhibitors; Extremities; Male; Microsomes, Liver; No-Observed-Adverse-Effect Level; Rats; Rats, Sprague-Dawley; Teratogens; Thalidomide; Toxicity Tests; Xenopus laevis | 2000 |
Design and synthesis of α-naphthoflavone chimera derivatives able to eliminate cytochrome P450 (CYP)1B1-mediated drug resistance via targeted CYP1B1 degradation.
Topics: Benzoflavones; Cell Line, Tumor; Cytochrome P-450 CYP1B1; Docetaxel; Drug Design; Drug Resistance, Neoplasm; Humans; Proteolysis; Thalidomide | 2020 |